DISA Limited Subsidiary Digital Life Line Launches Strategic Clinical Trial for Flagship AVAT Device at Ng Teng Fong General Hospital

Key Highlights

• Digital Life Line Pte. Ltd. (DLL), a subsidiary of DISA Limited, has commenced a four-month clinical trial of its Automated Visual Acuity Test (AVAT) device at Ng Teng Fong General Hospital (NTFGH).
• The trial marks a significant step in expanding DLL’s technology into mainstream and community healthcare settings, beyond tertiary specialist centres.
• This follows AVAT’s proven efficacy at Singapore’s National University Hospital, where the technology improved workflow efficiency and reduced patient wait times.
• The partnership with NTFGH represents a tangible opportunity to scale the AVAT technology across Singapore’s broader public health ecosystem.

Implications for Investors and Shareholders

• Market Expansion Potential: Success at NTFGH could catalyse widespread adoption of AVAT technology in high-volume community hospitals, opening a new and substantial market segment for DLL. This is a key strategic move to address the immense demand for ophthalmological services in mainstream healthcare settings.
• Recurring Revenue Opportunity: The clinical trial is positioned as a gateway for establishing recurring revenue streams from public healthcare institutions, which could materially impact future earnings.
• Operational Efficiency and Cost Reduction: The AVAT device automates traditional eye exams, enabling patients to self-administer accurate visual acuity tests with minimal supervision. This innovation frees up valuable time for healthcare professionals, allowing clinics to manage more patients and reduce operational costs.
• Technological Leadership: AVAT leverages proprietary optics and intuitive programming, underscoring DISA Limited’s commitment to disruptive innovation in healthcare technology. The company’s strong in-house R&D capabilities position it well for pursuing further innovations, including AI and IoT applications.
• Strategic Partnership and Endorsement: The collaboration is backed by NTFGH’s Head of Ophthalmology, Dr. Jamie Ng, who affirmed the potential of AVAT to enhance clinical efficiency and patient care. This endorsement from a major hospital increases the credibility and marketability of DLL’s technology.
• Share Price Sensitivity: Successful clinical validation and market acceptance of AVAT could have a material positive effect on DISA Limited’s valuation and share price, given the potential for scalable deployment, increased revenue, and operational efficiencies.

Additional Details About DISA Limited

DISA Limited is listed on the Singapore Catalist Stock Exchange and focuses on pioneering technology innovations to enhance outcomes and efficiencies in healthcare and consumer industries. The company is committed to leveraging artificial intelligence, IoT, and other digital solutions to optimise efficiency and quality standards in its targeted markets. More information is available at www.disa.sg.

Management Commentary

Eddie Chng, CEO of Digital Life Line:
“The trial at Ng Teng Fong General Hospital is the essential next step to demonstrate our technology’s core capability to make real-world impact. This partnership represents a tangible opportunity to replicate our success across the broader public health system, creating a recurring revenue stream.”

Dr. Jamie Ng, Head of Ophthalmology, NTFGH:
“We are pleased to collaborate with Digital Life Line on this innovative trial. The integration of automated technologies like AVAT has the potential to significantly enhance our clinical efficiency and patient care experience. We look forward to evaluating its performance in our community-based setting and exploring its benefits for our patients and staff.”

Investor Takeaway

The launch of this hospital trial is a potentially transformative development for DISA Limited and its subsidiary DLL. The move into community healthcare settings not only validates the AVAT technology but also opens doors to significant market expansion and recurring revenue opportunities. Investors should monitor the outcome of the trial and subsequent announcements, as successful validation and widespread adoption may have a material impact on DISA Limited’s future growth prospects and share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions related to DISA Limited or its subsidiaries. The information provided is based on company announcements and management commentary, and future outcomes may differ from projections.

View DISA W261218 Historical chart here